FGFR1 kinase inhibitors: Close regioisomers adopt divergent binding modes and display distinct biophysical signatures

ACS Medicinal Chemistry Letters

Volumn 5, Issue 2, 2014, Pages 166-171

  Klein, Tobias ^a   Tucker, Julie ^a   Holdgate, Geoffrey A ^a   Norman, Richard A ^a   Breeze, Alexander L ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

induced fit; isothermal titration calorimetry; protein ligand interactions; Receptor tyrosine kinase; surface plasmon resonance; X ray crystallography

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ARTICLE; BIOSENSOR; CHEMICAL STRUCTURE; CONFORMATIONAL TRANSITION; DRUG TARGETING; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

EID: 84894054642     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml4004205     Document Type: Article

References (25)

1. Eswarakumar, V. P.; Lax, I.; Schlessinger, J. Cellular signaling by fibroblast growth factor receptors Cytokine Growth Factor Rev. 2005, 16, 139-149 (Pubitemid 40616112)
2. Turner, N.; Grose, R. Fibroblast growth factor signalling: from development to cancer Nat. Rev. Cancer 2010, 10, 116-29
3. Koziczak, M.; Holbro, T.; Hynes, N. E. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins Oncogene 2004, 23, 3501-8 (Pubitemid 38658416)
4. Chen, G.; Tian, X.; Liu, Z.; Zhou, S.; Schmidt, B.; Henne-Bruns, D.; Bachem, M.; Kornmann, M. Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression Br. J. Cancer 2010, 102, 188-95
5. Feng, S.; Shao, L.; Yu, W.; Gavine, P.; Ittmann, M. Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression Clin. Cancer Res. 2012, 18, 3880-8
6. Zhang, Y.; Guo, K. J.; Shang, H.; Wang, Y. J.; Sun, L. G. Expression of aFGF, bFGF, and FGFR1 in ovarian epithelial neoplasm Chin. Med. J. (Engl.) 2004, 117, 601-3 (Pubitemid 38579085)
7. Katoh, M.; Nakagama, H. FGF Receptors: Cancer Biology and Therapeutics Med. Res. Rev. 2013, 10.1002/med.21288
8. Norman, R. A.; Schott, A.-K.; Andrews, D. M.; Breed, J.; Foote, K. M.; Garner, A. P.; Ogg, D.; Orme, J. P.; Pink, J. H.; Roberts, K.; Rudge, D. A.; Thomas, A. P.; Leach, A. G. Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase J. Med. Chem. 2012, 55, 5003-12
9. Ladbury, J. E. Just add water! The effect of water on the specificity of protein-ligand binding sites and its potential application to drug design Chem. Biol. 1996, 3, 973-980 (Pubitemid 27058821)
10. Mohammadi, M.; Froum, S.; Hamby, J. M.; Schroeder, M. C.; Panek, R. L.; Lu, G. H.; Eliseenkova, A. V.; Green, D.; Schlessinger, J.; Hubbard, S. R. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain EMBO J. 1998, 17, 5896-904 (Pubitemid 28474784)
11. Guagnano, V.; Furet, P.; Spanka, C.; Bordas, V.; Le Douget, M.; Stamm, C.; Brueggen, J.; Jensen, M. R.; Schnell, C.; Schmid, H.; Wartmann, M.; Berghausen, J.; Drueckes, P.; Zimmerlin, A.; Bussiere, D.; Murray, J.; Graus Porta, D. Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl- piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase J. Med. Chem. 2011, 54, 7066-7083
12. Tsai, J.; Lee, J. T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N. K.; Sproesser, K.; Li, L.; Smalley, K. S. M.; Fong, D.; Zhu, Y.-L.; Marimuthu, A.; Nguyen, H.; Lam, B.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S.-H.; Schlessinger, J.; Zhang, K. Y. J.; West, B. L.; Powell, B.; Habets, G.; Zhang, C.; Ibrahim, P. N.; Hirth, P.; Artis, D. R.; Herlyn, M.; Bollag, G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 3041-3046 (Pubitemid 351723664)
13. Bae, J. H.; Lew, E. D.; Yuzawa, S.; Tomé, F.; Lax, I.; Schlessinger, J. The Selectivity of Receptor Tyrosine Kinase Signaling Is Controlled by a Secondary SH2 Domain Binding Site Cell 2009, 138, 514-524
14. Eathiraj, S.; Palma, R.; Hirschi, M.; Volckova, E.; Nakuci, E.; Castro, J.; Chen, C.-R.; Chan, T. C. K.; France, D. S.; Ashwell, M. A. A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor J. Biol. Chem. 2011, 286, 20677-87
15. Mohammadi, M.; McMahon, G.; Sun, L.; Tang, C.; Hirth, P.; Yeh, B. K.; Hubbard, S. R.; Schlessinger, J. Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors Science 1997, 276, 955-960 (Pubitemid 27209095)
16. Tokarski, J. S.; Newitt, J. A.; Chang, C. Y. J.; Cheng, J. D.; Wittekind, M.; Kiefer, S. E.; Kish, K.; Lee, F. Y. F.; Borzillerri, R.; Lombardo, L. J.; Xie, D.; Zhang, Y.; Klei, H. E. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants Cancer Res. 2006, 66, 5790-7 (Pubitemid 43927133)
17. Nagar, B.; Hantschel, O.; Young, M. A.; Scheffzek, K.; Veach, D.; Bornmann, W.; Clarkson, B.; Superti-Furga, G.; Kuriyan, J. Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase Cell 2003, 112, 859-871 (Pubitemid 36378887)
18. Cowan-Jacob, S. W.; Fendrich, G.; Manley, P. W.; Jahnke, W.; Fabbro, D.; Liebetanz, J.; Meyer, T. The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation Structure 2005, 13, 861-871 (Pubitemid 40804389)
19. Kulagowski, J. J.; Blair, W.; Bull, R. J.; Chang, C.; Deshmukh, G.; Dyke, H. J.; Eigenbrot, C.; Ghilardi, N.; Gibbons, P.; Harrison, T. K.; Hewitt, P. R.; Liimatta, M.; Hurley, C. A.; Johnson, A.; Johnson, T.; Kenny, J. R.; Bir Kohli, P.; Maxey, R. J.; Mendonca, R.; Mortara, K.; Murray, J.; Narukulla, R.; Shia, S.; Steffek, M.; Ubhayakar, S.; Ultsch, M.; van Abbema, A.; Ward, S. I.; Waszkowycz, B.; Zak, M. Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors J. Med. Chem. 2012, 55, 5901-5921
20. Levy, Y.; Onuchic, J. N. Water Mediation in Protein Folding and Molecular Recognition Annu. Rev. Biophys. Biomol. Struct. 2006, 35, 389-415 (Pubitemid 43877384)
21. Connolly, C. J. C.; Hamby, J. M.; Schroeder, M. C.; Barvian, M.; Lu, G. H.; Panek, R. L.; Amar, A.; Shen, C.; Kraker, A. J.; Fry, D. W.; Klohs, W. D.; Doherty, A. M. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors Bioorg. Med. Chem. Lett. 1997, 7, 2415-2420 (Pubitemid 27412496)
22. Hajduk, P. J.; Sauer, D. R. Statistical Analysis of the Effects of Common Chemical Substituents on Ligand Potency J. Med. Chem. 2008, 51, 553-564 (Pubitemid 351252283)
23. Schwartz, P. A.; Murray, B. W. Protein kinase biochemistry and drug discovery Bioorg. Chem. 2011, 39, 192-210
24. Simard, J. R.; Getlik, M.; Grütter, C.; Schneider, R.; Wulfert, S.; Rauh, D. Fluorophore Labeling of the Glycine-Rich Loop as a Method of Identifying Inhibitors That Bind to Active and Inactive Kinase Conformations J. Am. Chem. Soc. 2010, 132, 4152-4160
25. Biela, A.; Nasief, N. N.; Betz, M.; Heine, A.; Hangauer, D.; Klebe, G. Dissecting the Hydrophobic Effect on the Molecular Level: The Role of Water, Enthalpy, and Entropy in Ligand Binding to Thermolysin Angew. Chem., Int. Ed. 2013, 52, 1822-1828